SCHEMBL25310328

SCHEMBL25310328

Nc1nc2ncc(-c3ccc(Cl)cn3)nc2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CASP3 P42574 2/20 0.33
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MYC P01106 1/20 0.32
WDR5 P61964 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
CLK1 P49759 1/20 0.32
SLC2A1 P11166 1/20 0.32
GRM5 P41594 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019074 1.00 TGFBR1 (0.41) TGFBR1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL31019104 0.83 SMN1; SMN2 (0.49) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL25307187 0.83 SMN1; SMN2 (0.49) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL30526908 0.80 TGFBR1 (0.44) TGFBR1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL31019057 0.78 CYP1A2 (0.39) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL25308880 0.78 GRM5 (0.36) ALDH1A1KDM4EGRM5L3MBTL1HTT
SCHEMBL25262609 0.78 EPHX2 (0.39) MAPTKMT2AHSD17B10CASP3ALDH1A1
SCHEMBL31019125 0.78 GRM5 (0.36) ALDH1A1KDM4EGRM5L3MBTL1HTT
SCHEMBL25309265 0.78 CYP1A2 (0.39) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL31019128 0.78 EPHX2 (0.39) MAPTKMT2AHSD17B10CASP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122221-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2025-04-17 US disclosed
EP-4464709-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2024-11-20 EP disclosed
WO-2023134739-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF 南京再明医药有限公司 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122221-A1 SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF POLRMT, POLQ, POLH TGFBR1 2529/4885SMN1; SMN2 1976/4885MAPT 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.